主 办:北 京 中 医 药 大 学
ISSN 1006-2157 CN 11-3574/R

JOURNAL OF BEIJIGN UNIVERSITY OF TRADITIONAL CHINE ›› 2015, Vol. 38 ›› Issue (8): 573-576.doi: 10.3969/j.issn.1006-2157.2015.08.015

Previous Articles    

A clinical study on the effects of supplemented Danggui Buxue Decoction on cytokines in IgA glomerulonephritic patients of kidney deficiency and blood stasis pattern*

WEI Ming-gang1, XIONG Pei-hua1#, SUN Wei2, HE Wei-ming2, ZHANG Ling1, FEI Mei1   

  1. 1 The First Affiliated Hospital, Soochow University, Jiangsu 215006;
    2 Nephrology Department, Jiangsu Provincial Hospital of Traditional Chinese Medicine
  • Received:2014-08-05 Online:2015-08-30 Published:2015-08-30

Abstract: Objective To investigate the effects of supplemented Danggui Buxue Tang (Chinese angelica blood-tonifying decoction) on inhibition of cytokine congregation and kidney cirrhosis in patients with IgA glomerulonephritis. Methods Histopathologically confirmed IgA grlomerulonephritic patients were randomly divided into two groups. Both groups received routine treatment while treatment group was given an extra supplemented Danggui Buxue Tang. Outcome measures were urine and blood cytokines and fibrosis related parameters to compare the differences between groups. Results 24h urine protein level was both reduced in treatment group (from 5.78±1.10 g to 1.25±0.67 g) and control group (from 5.25±1.21 g to 2.09±0.89 g). Cytokines and fibrosis related parameters including MCP-1, MIF, TGF-β1,HA, LN, Col-IV, and PIIINP were all significantly improved after intervention in both groups respectively (P<0.05). The difference between two groups was significant in all factors except LN. Conclusion Combined treatment of with conventional and Chinese medicine is effective for IgA glomerulonephritis in terms of inhibiting cytokine aggregation and delay kidney cirrhosis. Adding supplemented Danggui Buxue Tang according to TCM pattern identification seems to improve effectiveness significantly.

Key words: IgA nephropathy, Danggui Buxue Decoction, cytokines, renal fibrosis parameters, clinical study

CLC Number: 

  • R269.23